Computationally designed mRNA-launched protein nanoparticle vaccines.

ABSTRACT: Both protein nanoparticle and mRNA vaccines were clinically de-risked during the COVID-19 pandemic^1-6. These vaccine modalities have complementary strengths: antigen display on protein nanoparticles can enhance the magnitude, quality, and durability of antibody responses^7-10, while mRNA vaccines can be rapidly manufactured¹¹ and elicit antigen-specific CD4 and CD8 T cells^12,13. Here we leverage a computationally designed icosahedral protein nanoparticle that was redesigned for optimal secretion from eukaryotic cells¹⁴ to develop an mRNA-launched nanoparticle vaccine for SARS-CoV-2. The nanoparticle, which displays 60 copies of a stabilized variant of the Wuhan-Hu-1 Spike receptor binding domain (RBD)¹⁵, formed monodisperse,

SUBMITTER: Hendricks GG 

PROVIDER: S-EPMC11291046 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature